Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Projected top drug makers globally by revenue 2019

This statistic depicts the probable top 10 pharmaceutical companies by revenue in 2019 after the completion of the Takeda-Shire deal. After this deal, the new Takeda-Shire company would become one of the top 10 pharma companies globally. The same would be true for Bristol-Myers Squibb, if the deal with Celgene should be completed.

Probable top 10 pharmaceutical companies by revenue in 2019 after Takeda-Shire deal

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

January 2019

Region

Worldwide

Survey time period

as of January 2019

Supplementary notes

Estimates are based on the companies' filings for the most-recent fiscal year.
* BMS and Celgene's combined revenue dependent on deal completion; Exchange rates used are as of Jan. 4, 2019.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Scandinavia "

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.